References
- Ashkenazi A, Pai RC, Fong S et al (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155–162. doi:10.1172/JCI6926
- Azijli K, Weyhenmeyer B, Peters GJ et al (2013) Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: Discord in the death receptor family. Cell Death Differ 20: 858–868. doi:10.1038/cdd.2013.28
- Bai B, Chen H (2021) Metformin: A novel weapon against inflammation. Front Pharmacol 12:622262. doi: 10.3389/fphar.2021.622262
- Bavi P, Prabhakaran SE, Abubaker J et al (2010) Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations. Mol Cancer 9:203. doi:10.1186/1476-4598-9-203
- Berlec A, Završnik J, Butinar M et al (2015) In vivo imaging of Lactococcus lactis, Lactobacillus plantarum and Escherichia coli expressing infrared fluorescent protein in mice. Microb Cell Fact 14:181. doi:10.1186/s12934-015-0376-4
- Bosma GC, Custer RP, Bosma MJ (1983) A severe combined immunodeficiency mutation in the mouse. Nature 301:527–530. doi:10.1038/301527a0
- Bosma M (1991) The scid mouse mutant: Definition, characterization, and potential uses. Annu Rev Immunol 9:323–350. doi:10.1146/annurev.immunol.9.1.323
- Carvalho RD, Breyner N, Menezes-Garcia Z et al (2017) Secretion of biologically active pancreatitis-associated protein I (PAP) by genetically modified dairy Lactococcus lactis NZ9000 in the prevention of intestinal mucositis. Microb Cell Fact 16:27. doi:10.1186/s12934-017-0624-x
- Ciaćma K, Wiȩckiewicz J, Kȩdracka-Krok S et al (2018) Secretion of tumoricidal human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by recombinant Lactococcus lactis: Optimization of in vitro synthesis conditions. Microb Cell Fact 17:177. doi:10.1186/s12934-018-1028-2
- Cummins JM, Kohli M, Rago C et al (2004) X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res 64:3006–3008. doi:10.1158/0008-5472.CAN-04-0046
- DeRoche TC, Xiao SY, Liu X (2014) Histological evaluation in ulcerative colitis. Gastroenterol Rep 2:178–192. doi:10.1093/gastro/gou031
- Dinh CHL, Yu Y, Szabo A et al (2016) Bardoxolone methyl prevents high-fat diet-induced colon inflammation in mice. J Histochem Cytochem 64:237–255. doi:10.1369/0022155416631803
- Ehrhardt H, Fulda S, Schmid I et al (2003) TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB. Oncogene 22:3842–3852. doi:10.1038/sj.onc.1206520
- Evans JP, Sutton PA, Winiarski BK et al (2016) From mice to men: Murine models of colorectal cancer for use in translational research. Crit Rev Oncol Hematol 98:94–105. doi:10.1016/j.critrevonc.2015.10.009
- Galligan L, Longley DB, McEwan M et al (2005) Chemotherapy and TRAIL-mediated colon cancer cell death: The roles of p53, TRAIL receptors, and c-FLIP. Mol Cancer Ther 4:2026–2036. doi:10.1158/1535-7163.MCT-05-0262
- Ganten TM, Sykora J, Koschny R et al (2009) Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. J Mol Med 87:995–1007. doi:10.1007/s00109-009-0510-z
- Guilbaud N, Kraus-Berthier L, Meyer-Losic F et al (2001) Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors. Clin Cancer Res 7:2573–2580
- Hartwig T, Montinaro A, von Karstedt S et al (2017) The TRAIL-induced cancer secretome promotes a tumor-supportive immune microenvironment via CCR2. Mol Cell 65:730–742.e5. doi:10.1016/j.molcel.2017.01.021
- Herbst RS, Eckhardt SG, Kurzrock R et al (2010) Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 28:2839–2846. doi:10.1200/JCO.2009.25.1991
- Hernandez A, Wang Q, Schwartz SA et al (2001) Sensitization of human colon cancer cells to TRAIL-mediated apoptosis. J Gastrointest Surg 5:56–65. doi:10.1016/S1091-255X(01)80014-7
- Hosono K, Endo H, Takahashi H et al (2010) Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res 3:1077–1083. doi: 10.1158/1940-6207
- Jin Z, McDonald ER, Dicker DT et al (2004) Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem 279:35829–35839. doi:10.1074/jbc.M405538200
- Kaczmarek K, Więckiewicz J, Węglarczyk K et al. (2021) The anti-tumor effect of lactococcus lactis bacteria-secreting human soluble trail can be enhanced by metformin both in vitro and in vivo in a mouse model of human colorectal cancer. Cancers 13:3004. doi:10.3390/cancers13123004
- Kaler P, Augenlicht L, Klampfer L (2009) Macrophage-derived IL-1B stimulates Wnt signaling and growth of colon cancer cells: A crosstalk interrupted by vitamin D”3. Oncogene 28:3892–3902. doi:10.1038/onc.2009.247
- Kaler P, Galea V, Augenlicht L et al (2010) Tumor associated macrophages protect colon cancer cells from TRAIL-induced apoptosis through IL-1β-dependent stabilization of snail in tumor cells. PLoS One 5:e11700. doi:10.1371/journal.pone.0011700
- Kamarudin MNA, Sarker MMR, Zhou JR et al (2019) Metformin in colorectal cancer: molecular mechanism, preclinical and clinical aspects. J Exp Clin Cancer Res 38:491. doi: 10.1186/s13046-019-1495-2.
- Kelley SK, Harris LA, Xie D et al (2001) Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: Characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 299:31–38
- Klijn N, Weerkamp AH, De Vos WM (1995) Genetic marking of Lactococcus lactis shows its survival in the human gastrointestinal tract. Appl Environ Microbiol 61:2771–2774. doi:10.1128/aem.61.7.2771-2774.1995
- Kos B, Šušković J, Goreta J et al (2000) Effect of protectors on the viability of Lactobacillus acidophilus M92 in simulated gastrointestinal conditions. Food Technol Biotechnol 38:121–127
- Lemke J, Von Karstedt S, Zinngrebe J et al (2014) Getting TRAIL back on track for cancer therapy. Cell Death Differ 21: 1350–1364. doi:10.1038/cdd.2014.81
- Lin Y, Xu J, Lan H (2019) Tumor-associated macrophages in tumor metastasis: Biological roles and clinical therapeutic applications. J Hematol Oncol 12:76. doi:10.1186/s13045-019-0760-3
- Ma W, Chen J, Meng Y et al (2018) Metformin alters gut microbiota of healthy mice: Implication for its potential role in gut microbiota homeostasis. Front Microbiol 9:1336. doi:10.3389/fmicb.2018.01336
- Mantovani A, Sica A, Sozzani S et al (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25:677–686. doi:10.1016/j.it.2004.09.015
- Molloy AM, Ardill J, Tomkin GH (1980) The effect of metformin treatment on gastric acid secretion and gastrointestinal hormone levels in normal subjects. Diabetologia 19:93–96. doi:10.1007/BF00421851
- Ozawa F, Friess H, Kleeff J et al (2001) Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett 163:71–81. doi:10.1016/S0304-3835(00)00660-1
- Park SH, Lee DH, Kim JL et al (2016) Metformin enhances TRAIL-induced apoptosis by Mcl-1 degradation via Mule in colorectal cancer cells. Oncotarget 7:59503–59518. doi:10.18632/oncotarget.11147
- Pitti RM, Marsters SA, Ruppert S et al (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271:12687–12690. doi:10.1074/jbc.271.22.12687
- Saturno G, Valenti M, De Haven Brandon A et al (2013) Combining TRAIL with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling. Oncotarget 4:1185–1198. doi:10.18632/oncotarget.1162
- Takayama T, Katsuki S, Takahashi Y et al (1998) Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 339:1277–1284. doi: 10.1056/NEJM199810293391803
- Van Dijk M, Halpin-McCormick A, Sessler T et al (2013) Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways. Cell Death Dis 4:e702. doi:10.1038/cddis.2013.214
- Varfolomeev E, Maecker H, Sharp D et al (2005) Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem 280:40599–40608. doi:10.1074/jbc.M509560200
- von Karstedt S, Conti A, Nobis M et al (2015) Cancer cell-autonomous TRAIL-R signaling promotes KRAS-Driven cancer progression, invasion, and metastasis. Cancer Cell 27:561–573. doi:10.1016/j.ccell.2015.02.014
- Wang LX, Zhang SX, Wu HJ et al (2019) M2b macrophage polarization and its roles in diseases. J Leukoc Biol 106:345–358. doi:10.1002/JLB.3RU1018-378RR
- Wiley SR, Schooley K, Smolak PJ et al (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673–682. doi:10.1016/1074-7613(95)90057-8
- Wu H, Esteve E, Tremaroli V et al (2017) Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med 23:850–858. doi:10.1038/nm.4345
- Zhang Y, Davis C, Ryan J et al (2013) Development and characterization of a reliable mouse model of colorectal cancer metastasis to the liver. Clin Exp Metastasis 30:903–918. doi:10.1007/s10585-013-9591-8
- Zhao X, Li L, Starr TK et al (2017) Tumor location impacts immune response in mouse models of colon cancer. Oncotarget 8:54775–54787. doi:10.18632/oncotarget.18423